© Reuters. The emblem of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/file photograph
ZURICH (Reuters) – Swiss contract drug producer Lonza mentioned on Wednesday it has signed an settlement to amass the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for $1.2 billion in money.
Lonza plans to speculate round 500 million Swiss francs ($562.30 million) to improve the ability and improve capabilities on the web site to accommodate the subsequent technology of mammalian biologics therapies, the corporate mentioned in an announcement.
($1 = 0.8892 Swiss francs)